![]() |
|
|
Vol. 29, Issue 2, 159-165, February 2001
Merck Frosst Centre for Therapeutic Research, Pointe Claire-Dorval,
Québec, Canada (D.A.N.-G., J.M.S., N.C., S.D., Y.L., P.R.,
J.A.Y.); and Safety Assessment, Merck Research Laboratories, West
Point, Pennsylvania (R.D., D.P.)
The drug candidate DFP
[5,5-dimethyl-3-(2-isopropoxy)-4-(4-methanesulfonylphenyl)-2(5H)-furanone]
is a selective cyclooxygenase-2 inhibitor under evaluation for
analgesic and anti-inflammatory therapy. The in vitro metabolic
pathways (rat microsomes) involve hydroxylation of the isopropyl side
chain at either of two positions, the methyl or the methine, thus
producing a hydroxylated metabolite (DFHP) or a dealkylated metabolite
(DFH). DFH formation was the major pathway. Using hepatic microsomes
from rats treated with agents that induce specific CYP isozymes, it was
shown that the dexamethasone-inducible rat CYP3A isozyme(s) play a
major role in DFH formation. The roles of CYP3A1 and -3A2 were
confirmed with genetically engineered rat CYP enzymes. The potential
for induction of rat CYP3A by DFP was evaluated by incubating DFP in
rat hepatocyte cultures and measuring the CYP3A levels. Both CYP3A
immunoreactive protein and enzyme activity were induced in a
dose-dependent manner. The induction was confirmed in vivo by dosing
rats with DFP at 100 mg/kg for 4 days. Microsomes prepared from the
excised livers showed that DFP gave ~55% of the induction observed
with dexamethasone, as determined by Western blot. In vitro metabolic
auto-induction of DFP was assessed by measuring the metabolism of DFP
in hepatocytes treated with DFP. DFH formation was significantly
enhanced in the DFP-treated cells. In vivo, treating rats with DFP at
doses of 10 to 100 mg/(kg·day) for 13 weeks indicated that DFP
induced its own metabolism. The Cmax and
plasma drug area under the curve values during the thirteenth week were significantly lower than that on the first day, and the
effect was dose-dependent.
This article has been cited by other articles:
![]() |
R. Kitamura, Y. Yamamoto, S. Nagayama, and M. Otagiri Decrease in Plasma Concentrations of Antiangiogenic Agent TSU-68 ((Z)-5-[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid) during Oral Administration Twice a Day to Rats Drug Metab. Dispos., September 1, 2007; 35(9): 1611 - 1616. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Nicoll-Griffith, N. Chauret, R. Houle, S. H. Day, M. D'Antoni, and J. M. Silva USE OF A BENZYLOXY-SUBSTITUTED LACTONE CYCLOOXYGENASE-2 INHIBITOR AS A SELECTIVE FLUORESCENT PROBE FOR CYP3A ACTIVITY IN PRIMARY CULTURED RAT AND HUMAN HEPATOCYTES Drug Metab. Dispos., December 1, 2004; 32(12): 1509 - 1515. [Abstract] [Full Text] [PDF] |
||||